Technical Analysis for GLPG - Galapagos NV

Grade Last Price % Change Price Change
grade B 112.64 -0.19% -0.21
GLPG closed down 0.19 percent on Monday, May 20, 2019, on 54 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical GLPG trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Fell Below 20 DMA Bearish -0.19%
Bollinger Band Squeeze Range Contraction -0.19%
Narrow Range Bar Range Contraction -0.19%
NR7 Range Contraction -0.19%
20 DMA Support Bullish -1.45%
Bollinger Band Squeeze Range Contraction -1.45%
Crossed Above 20 DMA Bullish -1.45%

Older signals for GLPG ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn's disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.
Medicine Medical Specialties Immunology Autoimmune Diseases Monoclonal Antibodies Inflammation Psoriasis Rheumatoid Arthritis Inflammatory Bowel Disease Osteoarthritis Inflammatory Diseases Ulcerative Colitis Arthritis Abdominal Pain Colitis Treatment Of Inflammatory Diseases Treatment Of Inflammation
Is GLPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 125.48
52 Week Low 85.0
Average Volume 133,075
200-Day Moving Average 105.0536
50-Day Moving Average 111.6718
20-Day Moving Average 113.927
10-Day Moving Average 114.09
Average True Range 2.7027
ADX 9.54
+DI 25.3531
-DI 26.3674
Chandelier Exit (Long, 3 ATRs ) 109.2019
Chandelier Exit (Short, 3 ATRs ) 119.0281
Upper Bollinger Band 116.6176
Lower Bollinger Band 111.2364
Percent B (%b) 0.26
BandWidth 4.723375
MACD Line 0.0993
MACD Signal Line 0.5324
MACD Histogram -0.4332
Fundamentals Value
Market Cap 5.73 Billion
Num Shares 50.8 Million
EPS -0.70
Price-to-Earnings (P/E) Ratio -160.91
Price-to-Sales 23.11
Price-to-Book 3.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 115.53
Resistance 3 (R3) 115.77 115.05 115.05
Resistance 2 (R2) 115.05 114.31 114.93 114.89
Resistance 1 (R1) 113.84 113.86 113.48 113.60 114.73
Pivot Point 113.12 113.12 112.94 113.00 113.12
Support 1 (S1) 111.92 112.39 111.56 111.68 110.55
Support 2 (S2) 111.20 111.93 111.08 110.39
Support 3 (S3) 109.99 111.20 110.23
Support 4 (S4) 109.75